The role of endocannabinoid system blockade in the treatment of the metabolic syndrome (Q36773310)

16 August 2017

1 reference

title

The role of endocannabinoid system blockade in the treatment of the metabolic syndrome (English)

1 reference

16 August 2017

main subject

endocannabinoid system

0 references

1 reference

Dimitri P Mikhailidis

series ordinal

2

object named as

Dimitri P Mikhailidis

1 reference

16 August 2017

Anna I Kakafika

1

1 reference

16 August 2017

Asterios Karagiannis

series ordinal

3

1 reference

16 August 2017

Vasilios G Athyros

series ordinal

4

1 reference

16 August 2017

publication date

28 March 2007

1 reference

The Journal of Clinical Pharmacology

16 August 2017

published in

1 reference

16 August 2017

volume

47

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

642-652

1 reference

Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Targeting vascular risk in patients with metabolic syndrome but without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Rimonabant--a selective CB1 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

The endogenous cannabinoid system controls extinction of aversive memories

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Cannabinoid receptor localization in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Functional CB1 cannabinoid receptors in human vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Rimonabant: endocannabinoid inhibition for the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Is visceral obesity the cause of the metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Health consequences of visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Adiponectin and Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Plasma adiponectin levels and risk of myocardial infarction in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Adiponectin and protection against type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Leptin is associated with increased risk of myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

The triglyceride issue: a view from Framingham

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Münster Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

2nd International Symposium on triglycerides and HDL: metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Low density lipoprotein particle size and risk factors of insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Impaired fasting glycaemia resembles impaired glucose tolerance with regard to cardiovascular risk factors: population-based, cross-sectional study of risk factors for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Association of vascular risk factors with increasing glycemia even in normoglycemic subjects in an older Chinese population: the Guangzhou Biobank Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Endothelial dysfunction in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Diabetes and advanced glycation endproducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

C-Reactive Protein Is Independently Associated With Fasting Insulin in Nondiabetic Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Differentiation between obesity and insulin resistance in the association with C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Inflammatory markers and the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Weight loss reduces C-reactive protein levels in obese postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270007299358

21 January 2018

Identifiers

DOI

10.1177/0091270007299358

1 reference

16 August 2017

1 reference